Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: Recent Innovations on Biomedical Engineering
Guest editors: Wen-Hsiang Hsieh
Article type: Research Article
Authors: Song, Hye-Jeonga; b | Nam, Kyeong-Mina; b | Kim, Jong-Daea; b | Park, Chan-Younga; b | Kim, Yu-Seopa; b; *
Affiliations: [a] Department of Convergence Software, Hallym University, Chuncheon, Ganwon-do, Korea | [b] Bio-IT Research Center Hallym University, Chuncheon, Ganwon-do, Korea
Correspondence: [*] Corresponding authors: Yu-Seop Kim, Department of Convergence Software, Hallym University; Bio-IT Research Center Hallym University, Chuncheon, Ganwon-do, 2002-702, Korea. E-mail:yskim01@hallym.ac.kr
Abstract: We try to find out the best weight values of CA125 and HE4 in a discriminant formula classifying ovarian cancer patients from benign patients. We utilize a logistic regression analysis for the early screening system of the ovarian cancer for Korean patients. We compare our system with ROMA (Risk of Ovarian Malignancy Algorithm) of Abbot corp. In view of AUC (Area under the ROC curve), sensitivity with 95% of specificity and accuracy are considered. We performed experiments based on the logistic regression analysis separated by the case of pre- and post- menopausal stages and by the stages of progression of cancer. In our experiments, we can increase about 15.6% points of sensitivity with 95% of specificity, compared to that of ROMA. In premenopausal cases, ROMA shows 93.32% of AUC value and our system shows 97.48% of AUC, 4.1% points higher than ROMA. AUC of the ROMA for premenopausal women was 93.32%, whereas the AUC of our system was 97.48%. Furthermore, the AUC of the ROMA for early-staged ovarian cancer was 91.35%, whereas the AUC of our system was 97.22%, showing that the diagnostic performance of our system was superior over that of the ROMA in Korean patient cases.
Keywords: Risk of ovarian malignancy algorithm, CA125, HE4, tumor marker, ovarian cancer, sensitivity, specificity, epithelial ovarian cancer
DOI: 10.3233/THC-151065
Journal: Technology and Health Care, vol. 24, no. s1, pp. S163-S170, 2016
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl